This work was founded upon observations that JAM-A overexpression correlates with aggressive disease phenotypes in patients with breast cancer and that JAM-A levels can regulate those of HER2 in breast cancer cells [18, 19]. This evidence concerns the gene F11R and breast carcinoma.